胰高糖素样肽-1受体激动剂临床应用及研究进展
Glucagon-like peptide-1 receptor agonists:clinical applications and research progress
陈玉菲 1钟逸斐1
作者信息
- 1. 上海市中医药大学附属龙华医院 肾病科,上海 200032
- 折叠
摘要
胰高糖素样肽-1(GLP-1)受体激动剂是一类新型降糖药物,其降糖机制有别于传统降糖药,现被广泛应用于2 型糖尿病(T2DM)的治疗.随着临床证据的不断完善,很多国内外相关指南均推荐GLP-1受体激动剂(GLP-1RA)类药物用于T2DM的治疗.目前已有10种GLP-1RA在我国上市,这类药物由于自身结构与天然GLP-1同源性的差异,导致不同药物药代动力学和药效学等存在一定差异.本文对GLP-1RA类药物的药动学特性、临床应用,包括国内外适应证、不良反应及注意事项等做一总结.
Abstract
Glucagon-like peptide-1(GLP-1)receptor agonists represent a novel class of antihyperglycemic drugs,which differ from traditional antihyperglycemic drugs in their mechanisms of action and are now widely used in the treatment of type 2 diabetes mellitus(T2DM).As clinical evidence continues to accumulate,numerous domestic and international guidelines recommend the use of GLP-1 receptor agonists(GLP-1RAs)for T2DM management.Currently,10 GLP-1RAs have been marketed in China.These drugs exhibit variations in pharmacokinetics and pharmacodynamics due to differences in their structural homology with native GLP-1.This article summarizes the pharmacokinetic characteristics,clinical applications,including domestic and international indications,adverse reactions,and considerations of GLP-1RAs.
关键词
胰高血糖素样肽-1受体激动剂/2型糖尿病/药代动力学、药效学/合理用药Key words
glucagon-like peptide-1 receptor agonists/type 2 diabetes mellitus/pharmacokinetics,pharmacodynamics/rational use of drugs引用本文复制引用
出版年
2024
NETL
NSTL
万方数据